OFEV by Boehringer Ingelheim Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

OFEV's market opportunities lie in its broadening approval for various fibrosing lung diseases, including expansion to pediatric patients, strengthening its position as a leading treatment option. Its ...
Business Insider

Ofev (nintedanib) - Drug Insight and Market Forecast - 2030

New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Ofev (nintedanib) - Drug Insight and Market Forecast - 2030" - https ...
ksn.com

U.S. FDA accepts supplemental New Drug Application for OFEV® (nintedanib) for children and adolescents aged 6-17 years old with fibrosing interstitial lung disease

RIDGEFIELD, Conn. and INGELHEIM, Germany, July 25, 2023 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug ...
Cure Today

Drug Commonly Used to Treat Rare Lung Condition May Improve Survival in Patients With Bladder Cancer

Treatment with a combination of Ofev and chemotherapy was shown to have a survival benefit in a group of patients with bladder cancer. Although treatment with Ofev (nintedanib) —a targeted inhibitor ...
MedPage Today

Check SSc-ILD Patients on Ofev for Malnutrition, Study Suggests

During nintedanib (Ofev) treatment for interstitial lung disease associated with systemic sclerosis (SSc-ILD), clinicians prescribing the drug should be watchful for an unusual, indirect side effect, ...